睿知中国疾病研究地图
候选清单0

合肥安徽医科大学

安徽医科大学第一附属医院

First Affiliated Hospital of Anhui Medical University

在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

安徽医科大学第一附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma3 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma23 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma101 篇牵头论文
  4. 胃癌Stomach cancer84 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma13 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma10 篇牵头论文
  11. 再生障碍性贫血Aplastic anaemia1 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura2 篇牵头论文
  13. 范可尼贫血Fanconi anaemia1 篇牵头论文
  14. 重症肌无力Myasthenia gravis4 篇牵头论文
  15. 肝豆状核变性Wilson disease1 篇牵头论文
  16. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis7 篇牵头论文
  17. 大动脉炎Takayasu arteritis2 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis5 篇牵头论文
  19. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  20. IgA 肾病IgA nephropathy11 篇牵头论文
  21. 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
  22. 原发性胆汁性胆管炎Primary biliary cholangitis3 篇牵头论文
  23. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
  24. 先天性膈疝Congenital diaphragmatic hernia0 篇牵头论文
  25. 先天性巨结肠Hirschsprung disease1 篇牵头论文
  26. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa2 篇牵头论文
  27. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
  28. Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、成骨不全症、遗传性血管性水肿、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

合肥有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术影像与人工智能副作用与生活质量
论文中的科室耳鼻喉/头颈外科影像/核医学科放疗科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.8%。

牵头论文
23
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 4420232024: 4420242025: 11112025

合肥有 4 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-03
    登记号
    NCT07787273

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心合肥

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术分子标志物与基因
论文中的科室放疗科肿瘤内科
牵头的论文23
  1. CT-Based Deep Learning Predicts Prognosis in Esophageal Squamous Cell Cancer Patients Receiving Immunotherapy Combined with Chemotherapy.2025Academic radiology
  2. Correlative analysis of immune-related thyroid dysfunction and prognosis in patients with advanced esophageal squamous cell carcinoma.2025Anti-cancer drugs
  3. Radical surgery versus definitive radiotherapy in treatment of locoregional upper esophageal squamous cell carcinoma.2025BMC cancer免费全文
  4. Prognostic value of serum inflammatory markers in patients with esophageal squamous cell carcinoma undergoing surgery: a two-center retrospective cohort study.2025BMC cancer免费全文
  5. EZH2 suppresses IR-induced ferroptosis by forming a co-repressor complex with HIF-1α to inhibit ACSL4: Targeting EZH2 enhances radiosensitivity in KDM6A-deficient esophageal squamous carcinoma.2025Cell death and differentiation免费全文
  6. Radiomics and prognostic nutritional index for predicting postoperative survival in esophageal carcinoma.2025European journal of medical research免费全文
  7. SNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization.2025Frontiers in immunology免费全文
  8. Multi-Omics Analysis of Aberrances and Functional Implications of IRF5 in Digestive Tract Tumours.2025Journal of cellular and molecular medicine免费全文
  9. Patterns of Lymph Node Recurrence after Esophagectomy of pT2-3 N0M0 Esophageal Squamous Cell Carcinoma.2025Journal of gastrointestinal cancer免费全文
  10. Cervical Incision-Free Technique for R0 Resection in Cervicothoracic Esophageal Carcinoma: A Novel Approach of the Chai's Supra-Thoracic Apex Technique.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. Cancer-associated fibroblasts derived-exosomal circ_0076535 promotes esophageal squamous cell carcinoma progression.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  12. Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy.2024Annali italiani di chirurgia
  13. Risk factors for postoperative recurrence of pT2-3N0M0 esophageal squamous cell carcinoma and patterns of its recurrence.2024Bioscience trends
  14. Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer.2024Cancer medicine免费全文
  15. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.2024The Kaohsiung journal of medical sciences免费全文
  16. Acacetin restrains the malignancy of esophageal squamous carcinoma cells via regulating JAK2/STAT3 pathway.2023Chemical biology & drug design
  17. Circ_0008726 promotes malignant progression of ESCC cells through miR-206/HOXA13 pathway.2023General thoracic and cardiovascular surgery
  18. Prognostic analysis of radiotherapy for cervical lymph node recurrence after curative resection of thoracic esophageal squamous cell carcinoma.2023Journal of radiation research免费全文
  19. Prognostic nomogram and risk factors for predicting survival in patients with pT2N0M0 esophageal squamous carcinoma.2023Scientific reports免费全文
  20. Esophageal stenosis as an independent factor of poor prognosis in patients with ESCC treated with definitive chemoradiotherapy.2022Future oncology (London, England)
  21. LncRNA PTPRG-AS1 facilitates glycolysis and stemness properties of esophageal squamous cell carcinoma cells through miR-599/PDK1 axis.2022Journal of gastroenterology and hepatology
  22. GFI1 promotes the proliferation and migration of esophageal squamous cell carcinoma cells through the inhibition of SOCS1 expression.2021International journal of molecular medicine免费全文
  23. Effect of TRPM2-Mediated Calcium Signaling on Cell Proliferation and Apoptosis in Esophageal Squamous Cell Carcinoma.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma状态不明NCT07050576牵头方2024-05 启动
  2. Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment状态不明NCT03224221牵头方II期2017-03 启动
  3. Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma正在招募NCT07787273研究中心II期2026-03 启动
  4. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  5. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  6. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
PubMed 以外找到的论文(未计入)23
  1. 2145P Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: Primary efficacy/safety results and exploratory single-cell RNA sequencing correlates from a multicenter, prospect2025Annals of Oncology论文
  2. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncology会议摘要
  3. Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.2025Journal of Clinical Oncology论文
  4. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncology论文
  5. YWHAZ-Mediated Modulation of Tumor Differentiation Impact on the Long-Term Prognosis in Esophageal Squamous Cell Carcinoma Patients Following Chemoradiotherapy2025Research Square预印本
  6. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  7. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  8. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  9. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figshare数据集
  10. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  11. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figshare数据集
  12. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  13. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  14. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  15. Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospec2023Journal of Clinical Oncology会议摘要
  16. The role of PMI in evaluating the efficacy of PD-1 inhibitors and prognosis of patients treated for advanced esophageal squamous cell carcinoma2023Research Square预印本
  17. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncology会议摘要
  18. DNMT3A promotes the proliferation and metastasis of esophageal squamous cell carcinoma via upregulating HDAC92022Research Square预印本
  19. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集
  20. A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.2021Journal of Clinical Oncology会议摘要
  21. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  22. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  23. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 101 篇,占 0.7%。

牵头论文
101
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 171720212022: 141420222023: 151520232024: 252520242025: 28282025

合肥有 3 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  2. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  3. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  4. 即将招募
    NK521 in the Treatment of Advanced Solid Tumors
    分期
    早期I期
    开始
    2027-01
    登记号
    NCT07657416

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心合肥

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科肿瘤内科影像/核医学科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文101
  1. COA6 deficiency inhibits hepatocellular carcinoma progression by regulating cuproptosis through the JAK/STAT signaling pathway.2026Biochimica et biophysica acta. Molecular cell research
  2. Genetically engineered pig-to-human liver xenotransplantation.2026Journal of hepatology
  3. Nuclear Overexpression of SAMHD1 Induces M Phase Stalling in Hepatoma Cells and Suppresses HCC Progression by Interacting with the Cohesin Complex.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Causal role of immune cells in primary liver cancer: a mendelian randomization study.2025BMC cancer免费全文
  6. Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis.2025BMC cancer免费全文
  7. Synthesis and biological evaluation of 68Ga-DOTA-AngII as a radiotracer for PET/MR imaging of hepatocellular carcinoma.2025Bioorganic & medicinal chemistry
  8. Efficacy and Safety of Microwave Ablation in Patients With Hepatocellular Carcinoma With Decompensated Liver Cirrhosis: A Retrospective Study.2025Canadian journal of gastroenterology & hepatology免费全文
  9. RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis.2025Cancer immunology, immunotherapy : CII免费全文
  10. Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.2025Cancer science免费全文
  11. Endoplasmic reticulum stress-related super enhancer promotes epithelial-mesenchymal transformation in hepatocellular carcinoma through CREB5 mediated activation of TNC.2025Cell death & disease免费全文
  12. Targeting NAT10 attenuates homologous recombination via destabilizing DNA:RNA hybrids and overcomes PARP inhibitor resistance in cancers.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  13. Multi-modality model predicts lung metastasis of hepatocellular carcinoma using MRI and pathological: a retrospective multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  14. A real-world drug safety surveillance study of lenvatinib from the FAERS database.2025Expert opinion on drug safety
  15. NPC1 promotes the progression of hepatocellular carcinoma by mediating the accumulation of neutrophils into the tumor microenvironment.2025FEBS open bio免费全文
  16. The immunomodulatory role of the MAFB gene in hepatocellular carcinoma and its impact on biological activities.2025Gene
  17. Chemokines and PI3K/AKT signaling pathway mediate the spontaneously ruptured hepatocellular carcinoma through the regulation of the cell cycle.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  18. NME2 modulates HCC progression through 4EBP1 phosphorylation and autophagy regulation independent of mTOR.2025Hepatology communications免费全文
  19. Exosomes Derived from Endoplasmic Reticulum Stressed Hepatocellular Carcinoma Cells Enhance the Antitumor Immunity of Dendritic Cells.2025Inflammation
  20. Antitumor Effects of Tumor-Derived Exosomes in Murine Hepatocellular Carcinoma Models.2025Iranian journal of immunology : IJI
  21. Acid Sensor Acid-Sensing Ion Channel 1a Promotes Malignant Cell Proliferation Through the Transcription Factor 7/c-Myc Pathway in Liver Cancer.2025Laboratory investigation; a journal of technical methods and pathology
  22. Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study.2025Medicine免费全文
  23. NLR Risk Score for Predicting Patient Prognosis in Hepatocellular Carcinoma and Identification of Oncogenic Role of NLRP5 in Hepatocellular Carcinoma.2025Oncology research免费全文
  24. Novel Stemness-Associated Scores: Enhancing Predictions of Hepatocellular Carcinoma Prognosis and Tumor Immune Microenvironment.2025Oncology research免费全文
  25. Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer.2025Pathogens (Basel, Switzerland)免费全文
  26. LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis.2025PloS one免费全文
  27. The prognostic value and functional role of CPSF3 in hepatocellular carcinoma.2025Scientific reports免费全文
  28. SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma.2025Scientific reports免费全文
  29. IL35 modulates HBV-related HCC progression via IL6-STAT3 signaling.2025Scientific reports免费全文
  30. Efficacy of Perioperative Application of Enhanced Recovery After Surgery on Elderly Recipients Underwent Liver Transplantation.2025World journal of surgery
  31. Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.2024Abdominal radiology (New York)
  32. Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies-Development and Validation of the ABPS Score.2024Academic radiology
  33. Upregulation of multiple key molecules is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma by bulk and single-cell RNA-seq.2024Aging免费全文
  34. Gene variation profile and the potential correlation with clinical characteristics in HBV-associated HCC.2024Asian journal of surgery
  35. Comprehensive Analysis of TICRR in Hepatocellular Carcinoma Based on Bioinformatics Analysis.2024Biochemical genetics免费全文
  36. SEC24C suppresses the propagation and chemoresistance of hepatocellular carcinoma by promoting unfolded protein response-related apoptosis.2024Bioscience trends
  37. Preoperative Serum Glycan Levels Reflect Progression of Patients With Hepatocellular Carcinoma.2024Cancer medicine免费全文
  38. Prognostic and immune roles of UROC1 in human cancers: from mechanism exploration of NAFLD and HCC to pan-cancer analysis.2024European review for medical and pharmacological sciences
  39. Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway.2024International immunopharmacology
  40. Current Progress of Ferroptosis Study in Hepatocellular Carcinoma.2024International journal of biological sciences免费全文
  41. Function of microRNA‑124 in the pathogenesis of cancer (Review).2024International journal of oncology免费全文
  42. Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression.2024Journal of cellular and molecular medicine免费全文
  43. Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma.2024Journal of experimental & clinical cancer research : CR免费全文
  44. Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.2024Journal of nanobiotechnology免费全文
  45. Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma.2024Journal of translational medicine免费全文
  46. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.2024La Radiologia medica
  47. Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study.2024Medicine免费全文
  48. Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines.2024Molecular biology reports
  49. Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma.2024Molecular cancer免费全文
  50. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation.2024Oncogene
  51. TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.2024Oncogene免费全文
  52. Causal effect of porphyria biomarkers on alcohol-related hepatocellular carcinoma through Mendelian Randomization.2024PloS one免费全文
  53. A pan-cancer analysis uncovering the function of CRHBP in tumor immunity, prognosis and drug response: especially its function in LIHC.2024Scientific reports免费全文
  54. Based on Gadolinium Ethoxybenzyl DTPA-Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma.2024Technology in cancer research & treatment免费全文
  55. Interactive model for predicting the oncological outcome of patients with early-stage huge hepatocellular carcinoma after hepatectomy: a multicenter population-based study.2024Updates in surgery
  56. Contrast-Enhanced Ultrasound with Deep Learning with Attention Mechanisms for Predicting Microvascular Invasion in Single Hepatocellular Carcinoma.2023Academic radiology
  57. Combining WGCNA and machine learning to construct immune-related EMT patterns to predict HCC prognosis and immune microenvironment.2023Aging免费全文
  58. Circular RNA circ_0003028 regulates cell development through modulating miR-498/ornithine decarboxylase 1 axis in hepatocellular carcinoma.2023Anti-cancer drugs
  59. Cellular senescence-related genes: predicting prognosis in hepatocellular carcinoma.2023BMC cancer免费全文
  60. Oncological prognosis and morbidity of hepatectomy in elderly patients with hepatocellular carcinoma: a propensity score matching and multicentre study.2023BMC surgery免费全文
  61. COL15A1 interacts with P4HB to regulate the growth and malignancy of HepG2.2.15 cells.2023Biochemical and biophysical research communications
  62. miR-210 promotes hepatocellular carcinoma progression by modulating macrophage autophagy through PI3K/AKT/mTOR signaling.2023Biochemical and biophysical research communications免费全文
  63. Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma.2023Cancer medicine免费全文
  64. H2AFX might be a prognostic biomarker for hepatocellular carcinoma.2023Cancer reports (Hoboken, N.J.)免费全文
  65. miR-29c Suppresses the Malignant Phenotype of Hepatocellular Carcinoma Cells In Vitro by Mediating TPX2 Associated with Immune Infiltration.2023Digestive diseases and sciences
  66. Let-7c-5p down-regulates immune-related CDCA8 to inhibit hepatocellular carcinoma.2023Functional & integrative genomics
  67. Experimental models of fatty liver diseases: Status and appraisal.2023Hepatology communications免费全文
  68. Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehensive bioinformatics analysis.2023Medicine免费全文
  69. Liquid Biopsy in Hepatocellular Carcinoma.2023Methods in molecular biology (Clifton, N.J.)
  70. Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment.2023Neoplasma
  71. Comprehensive analysis of the expression and prognosis for IQ motif-containing GTPase-activating proteins in hepatocellular carcinoma.2022BMC cancer免费全文
  72. HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression.2022Biochemical and biophysical research communications
  73. Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis.2022Bioengineered免费全文
  74. Circular RNA hsa_circ_0006091 as a novel biomarker for hepatocellular carcinoma.2022Bioengineered免费全文
  75. ARHGEF2/EDN1 pathway participates in ER stress-related drug resistance of hepatocellular carcinoma by promoting angiogenesis and malignant proliferation.2022Cell death & disease免费全文
  76. CAF-Released Exosomal miR-20a-5p Facilitates HCC Progression via the LIMA1-Mediated β-Catenin Pathway.2022Cells免费全文
  77. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.2022Clinics and research in hepatology and gastroenterology
  78. Gene Signature and Prognostic Value of Ubiquitin-Specific Proteases Members in Hepatocellular Carcinoma and Explored the Immunological Role of USP36.2022Frontiers in bioscience (Landmark edition)
  79. A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors.2022Frontiers in immunology免费全文
  80. SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis.2022International journal of biological sciences免费全文
  81. Development and validation of safety and efficacy-associated risk calculator for hepatocellular carcinoma in the elderly after resection (SEARCHER): A multi-institutional observational study.2022International journal of surgery (London, England)
  82. Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma.2022Journal of nanobiotechnology免费全文
  83. Hemoglobin/Red Blood Cell Distribution Width Ratio in Peripheral Blood Is Positively Associated with Prognosis of Patients with Primary Hepatocellular Carcinoma.2022Medical science monitor : international medical journal of experimental and clinical research免费全文
  84. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis.2022Oxidative medicine and cellular longevity免费全文
  85. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.2021Anti-cancer drugs免费全文
  86. Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis.2021Asian journal of surgery
  87. Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinoma.2021BMC cancer免费全文
  88. Development and Validation of an Autophagy-Related Gene Signature for Predicting the Prognosis of Hepatocellular Carcinoma.2021BioMed research international免费全文
  89. Immune implication of FAM83D gene in hepatocellular carcinoma.2021Bioengineered免费全文
  90. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma.2021Bioengineered免费全文
  91. The mechanisms of renin-angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  92. Association between socioeconomic status and survival in patients with hepatocellular carcinoma.2021Cancer medicine免费全文
  93. Two novel online nomograms for predicting the survival of individual patients undergoing partial hepatectomy for huge hepatocellular carcinoma.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  94. Histone deacetylase‑2: A potential regulator and therapeutic target in liver disease (Review).2021International journal of molecular medicine免费全文
  95. PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma.2021Oncoimmunology免费全文
  96. BACH1 is transcriptionally inhibited by TET1 in hepatocellular carcinoma in a microRNA-34a-dependent manner to regulate autophagy and inflammation.2021Pharmacological research
  97. Screening, clinical features and prognostic analysis of liver cirrhosis-related hepatocellular carcinoma.2021Scandinavian journal of gastroenterology
  98. Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study.2021Technology in cancer research & treatment免费全文
  99. Identification of Key Genes for Hepatitis Delta Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis.2021The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  100. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.2021Transplant immunology
  101. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis.2021World journal of surgical oncology免费全文
中文论文(未计入)1
  1. [Applications and challenges of pathomics technique in the management of hepatocellular carcinoma].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. NK521 in the Treatment of Advanced Solid Tumors即将招募NCT07657416研究中心早期I期2027-01 启动
  2. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  4. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  5. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  6. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  7. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  8. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动
  9. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  10. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  11. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  12. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  13. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  14. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  15. Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma已完成NCT01210495研究中心II期2010-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 84 篇,占 0.9%。

牵头论文
84
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 161620212022: 121220222023: 222220232024: 131320242025: 19192025

合肥有 4 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期影像与人工智能手术
论文中的科室普外/肝胆胰外科肿瘤内科消化/肝病科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文84
  1. Mechanism of triptolide in the treatment of gastric cancer with diabetes through JAK2/STAT3 pathway.2026European journal of pharmacology
  2. Ephrin‑B2 promotes gastric cancer growth by inhibiting apoptosis and regulating the cell cycle via the Wnt/β‑catenin signaling pathway.2026International journal of oncology免费全文
  3. Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review.2025Biological research免费全文
  4. RORα inhibits proliferation and chemoresistance through AKR1A1-induced glucose and lipid reprogramming in gastric cancer.2025Cellular signalling
  5. The Solute Carrier Family 47 Member 1, Transcriptionally Regulated by GATA Binding Protein 6, Inhibits Ferroptosis in Gastric Cancer.2025DNA and cell biology
  6. The role of CSTF2 in gastric cancer: implications for therapy.2025European journal of medical research免费全文
  7. HEG1 promotes gastric cancer progression by stabilizing AKT1 and is functionally regulated by the deubiquitinase USP48.2025European journal of medical research免费全文
  8. Investigating the relationship between tongue diagnosis features and gastric cancer: A machine learning-based prediction model.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Construction of nomogram prognostic model for gastric signet ring cell carcinoma: Signet ring cell proportion influencing prognosis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. ELAVL1 facilitates gastric cancer progression and metastasis through TL1A mRNA stabilization.2025Experimental cell research
  11. Identification of an M1 Macrophages-Related Signature for Predicting the Survival and Therapeutic Response in Gastric Cancer.2025IET systems biology免费全文
  12. Nomogram for predicting primary resistance to anti-PD-1 therapy in advanced gastric cancer based on dynamic inflammatory markers: a multicenter retrospective study.2025International immunopharmacology
  13. Timing of Adjuvant Chemotherapy After Gastrectomy in Patients With Stage II to III Gastric Cancer: A Target Trial Emulation Study.2025JCO precision oncology
  14. NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism.2025Molecular medicine (Cambridge, Mass.)免费全文
  15. Complex intervention based on protective factors to improve resilience for gastric cancer patients: Mixed-methods process evaluation protocol.2025PloS one免费全文
  16. A prognostic risk prediction model for gastric cancer based on the EFNA4 and ETS1 regulatory axis in tumor cells.2025Scientific reports免费全文
  17. Integrin β5 interacts with G3BP1 through activating FAK/Src signaling pathway to promote gastric carcinogenesis.2025Scientific reports免费全文
  18. Muscle-Driven prognostication in gastric cancer: A multicenter deep learning framework integrating Iliopsoas and erector spinae radiomics for 5-Year survival prediction.2025Scientific reports免费全文
  19. Alcohol dehydrogenase iron containing 1 (ADHFE1) is associated with liver metastasis and regulates cellular function of gastric cancer.2025The International journal of biological markers
  20. Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer.2025World journal of gastroenterology免费全文
  21. The PVT1-214/miR-671-5p/SLC45A4 signaling axis regulates cell proliferation in human gastric cancer.2025World journal of surgical oncology免费全文
  22. UBR1 is a prognostic biomarker and therapeutic target associated with immune cell infiltration in gastric cancer.2024Aging免费全文
  23. SLAMF8 can predict prognosis of pan-cancer and the immunotherapy response effectivity of gastric cancer.2024Aging
  24. Identification of BANF1 as a novel prognostic biomarker in gastric cancer and validation via in-vitro and in-vivo experiments.2024Aging免费全文
  25. LncRNA UCA1 promotes vasculogenic mimicry by targeting miR-1-3p in gastric cancer.2024Carcinogenesis
  26. Pan-cancer analysis of TMEM45A and exploration of its prognostic value and mechanism in gastric cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  27. Helicobacter pylori promotes gastric cancer progression by activating the TGF-β/Smad2/EMT pathway through HKDC1.2024Cellular and molecular life sciences : CMLS免费全文
  28. miR-135b-5p promotes gastric carcinogenesis by targeting CLIP4-mediated JAK2/STAT3 signal pathway.2024Cellular signalling
  29. GRWD1 Over-Expression Promotes Gastric Cancer Progression by Activating Notch Signaling Pathway via Up-Regulation of ADAM17.2024Digestive diseases and sciences
  30. Integrated single-cell RNA sequencing reveals the tumor heterogeneity and microenvironment landscape during liver metastasis in adenocarcinoma of esophagogastric junction.2024Frontiers in immunology免费全文
  31. BNIP3 and DAPK1 methylation in peripheral blood leucocytes are noninvasive biomarkers for gastric cancer.2024Gene
  32. NFS1 inhibits ferroptosis in gastric cancer by regulating the STAT3 pathway.2024Journal of bioenergetics and biomembranes
  33. Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway.2024Journal of cancer research and clinical oncology免费全文
  34. Exploring the Influence of T Cell Marker Gene Expression on the Pathobiology and Clinical Prognostic Outcomes in Intestinal-Type Gastric Carcinoma.2024Journal of gastrointestinal cancer
  35. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.2023BMC cardiovascular disorders免费全文
  36. Risk of lymph node metastasis and feasibility of endoscopic submucosal dissection in undifferentiated-type early gastric cancer.2023BMC gastroenterology免费全文
  37. Comprehensive analysis of the biological function and immune infiltration of SLC38A2 in gastric cancer.2023BMC gastroenterology免费全文
  38. Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.2023Cancer gene therapy
  39. Incorporation of liver chemistry score in predicting survival of liver-involved advanced gastric cancer patients who received palliative chemotherapy.2023Cancer medicine免费全文
  40. Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer.2023Cell cycle (Georgetown, Tex.)免费全文
  41. Lysine-specific Demethylase 6A Upregulates Cadherin-1 and Accelerates Gastric Cancer Growth.2023Current pharmaceutical biotechnology
  42. Prognostic value of tumor deposits in lymph node-negative gastric cancer: A propensity score matching study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  43. Incidence and mortality trends in gastric cancer in the United States, 1992-2019.2023International journal of cancer
  44. Prognostic significance of post-preoperative tumor markers increments in patients with non-metastatic gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  45. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  46. Comparison of different risk stratifications for gastric cancer and establishing a simplified risk-scoring model based on the Kyoto classification.2023Journal of gastroenterology and hepatology
  47. Prediction of overall survival after radical gastrectomy using nomograms created by tumor markers.2023Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  48. Oral microbiota disorder in GC patients revealed by 2b-RAD-M.2023Journal of translational medicine免费全文
  49. Demethylase FTO enhances the PI3K/Akt signaling to promote gastric cancer malignancy.2023Medical oncology (Northwood, London, England)
  50. Downregulated KDM6A mediates gastric carcinogenesis via Wnt/β-catenin signaling pathway mediated epithelial-to-mesenchymal transition.2023Pathology, research and practice
  51. PGAM5 promotes tumorigenesis of gastric cancer cells through PI3K/AKT pathway.2023Pathology, research and practice
  52. Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer.2023Redox biology免费全文
  53. Efficacy and safety of esophageal submucosal tumors treated with internal traction method-assisted submucosal tunneling endoscopic resection: a single-center, single-blind, randomized controlled study.2023Surgical endoscopyRCT
  54. A Nomogram Based on the Log Odds of Positive Lymph Nodes Predicts the Prognosis of Patients with Colon Neuroendocrine Tumors After Surgery: A Surveillance, Epidemiology, and End Results Population-Based Study.2023Technology in cancer research & treatment免费全文
  55. Tousled-like kinase 1 promotes gastric cancer progression by regulating the tumor growth factor-beta signaling pathway.2023World journal of gastroenterology免费全文
  56. Comparison of the clinical and prognosis risk factors between endoscopic resection and radical gastrectomy for early-stage gastric cancer.2023World journal of surgical oncology免费全文
  57. LncRNA CRYM-AS1 Inhibits Gastric Cancer Progression via Epigenetically Regulating CRYM.2022Annals of clinical and laboratory science
  58. Hyperglycemia induces miR-26-5p down-regulation to overexpress PFKFB3 and accelerate epithelial-mesenchymal transition in gastric cancer.2022Bioengineered免费全文
  59. SAMHD1, positively regulated by KLF4, suppresses the proliferation of gastric cancer cells through MAPK p38 signaling pathway.2022Cell cycle (Georgetown, Tex.)免费全文
  60. Combined Non-Invasive Prediction and New Biomarkers of Oral and Fecal Microbiota in Patients With Gastric and Colorectal Cancer.2022Frontiers in cellular and infection microbiology免费全文
  61. A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients.2022Frontiers in immunology免费全文
  62. A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma.2022Frontiers in immunology免费全文
  63. Icariin inhibits gastric cancer cell growth by regulating the hsa_circ_0003159/miR-223-3p/NLRP3 signaling axis.2022Human & experimental toxicology
  64. TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer.2022International immunopharmacology
  65. A model established using marital status and other factors from the Surveillance, Epidemiology, and End Results database for early stage gastric cancer.2022Journal of investigative medicine : the official publication of the American Federation for Clinical Research免费全文
  66. circ_0044516 functions in the progression of gastric cancer by modulating MicroRNA-149-5p/HuR axis.2022Molecular and cellular biochemistry
  67. The Impact of a Simplified Scoring System on Long-Term Survival Outcomes in Patients with Gastric Cancer Undergoing Gastrectomy.2022Nutrition and cancer
  68. Prognostic significance of metastatic lymph node ratio in patients with gastric cancer after curative gastrectomy: a single-center retrospective study.2022Scandinavian journal of gastroenterology
  69. Circ_002059 suppresses cell proliferation and migration of gastric cancer via miR-182/MTSS1 axis.2021Acta biochimica et biophysica Sinica
  70. Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma.2021BMC cancer免费全文
  71. Prognostic value of different lymph node staging methods for node-positive cardia gastric cancer: a register-based retrospective cohort study.2021BMJ openRCT免费全文
  72. Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR-616-5p/DUSP2 axis.2021Basic & clinical pharmacology & toxicology
  73. Elevated expression of NFE2L3 promotes the development of gastric cancer through epithelial-mesenchymal transformation.2021Bioengineered免费全文
  74. Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  75. Peripheral Blood-Based DNA Methylation of Long Non-Coding RNA H19 and Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promoters are Potential Non-Invasive Biomarkers for Gastric Cancer Detection.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  76. Development and validation of a prognostic nomogram for gastric marginal zone lymphoma: a Surveillance, Epidemiology and End Results-based population study.2021Future oncology (London, England)
  77. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.2021International immunopharmacology
  78. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.2021Investigational new drugs
  79. Downregulating circRNA_0044516 Inhibits Cell Proliferation in Gastric Cancer Through miR-149/Wnt1/β-catenin Pathway.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  80. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.2021Journal of molecular medicine (Berlin, Germany)
  81. RORα and REV-ERBα are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer.2021Technology in cancer research & treatment免费全文
  82. Diagnostic Accuracy of Double Contrast-Enhanced Ultrasonography in Clarifying Tumor Depth (T Stage) of Gastric Cancer: Meta-analysis.2021Ultrasound in medicine & biology
  83. A novel method for π-shaped esophagojejunostomy and double-tract reconstruction (DTR) as an alternative in totally laparoscopic or robotic proximal gastrectomy for treating upper third proximal early gastric cancer.2021Updates in surgery
  84. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection状态不明NCT03817268牵头方III期2019-01 启动
  2. The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province状态不明NCT03333967牵头方2017-09 启动
  3. The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer状态不明NCT01964027牵头方(推断)II期2013-10 启动
  4. Diagnosis of Gastric Lesions From Exhaled Breath and Saliva已完成NCT01420588牵头方(推断)2011-08 启动
  5. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  6. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia已完成NCT05606094研究中心2023-03 启动
  7. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  8. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  9. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  11. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer状态不明NCT04139135研究中心III期2019-12 启动
  12. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  13. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)已完成NCT03399110研究中心III期2018-01 启动
  14. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor状态不明NCT03399253研究中心II/III期2017-12 启动
  15. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  16. Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.已撤回NCT02736552研究中心III期2016-03 启动
  17. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)已完成NCT02745509研究中心不分期2016-03 启动
  18. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  19. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

合肥有 3 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Expression of autophagy-related protein LC3B, p62, and cytoplasmic p53 in human retinoblastoma tissues.2016European review for medical and pharmacological sciences

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 2220242025: 552025

合肥有 10 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. Dose-Dependent Ferroptosis Induction in Osteosarcoma via NRF2/GPX4 Axis Modulation by Plasma-Activated Liquid Therapy.2026Antioxidants & redox signaling
  2. CLEC5A suppresses cell growth and metastasis via interfering with the calcineurin/NFATc1 signaling pathway in osteosarcoma.2025Experimental cell research
  3. Prognostic and Therapeutic Significance of Cancer-Associated Fibroblasts Genes in Osteosarcoma Based on Bulk and Single-Cell RNA Sequencing Data.2025Journal of cellular and molecular medicine
  4. Tenascin-C-enriched extracellular vesicles contribute to osteosarcoma progression via regulation of the angiotensin II receptor type 1 pathway.2025Journal of molecular histology
  5. A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy.2025Journal of nanobiotechnology
  6. NEK2 promotes the progression of osteosarcoma through the AKT/p-AKT pathway and interacts with FoxM1.2025Medical oncology (Northwood, London, England)
  7. Controllable All-in-One Biomimetic Hollow Nanoscaffold Initiating Pyroptosis-Mediated Antiosteosarcoma Targeted Therapy and Bone Defect Repair.2024ACS applied materials & interfaces
  8. In situ hydrogel based on Cu-Fe3O4 nanoclusters exploits oxidative stress and the ferroptosis/cuproptosis pathway for chemodynamic therapy.2024Biomaterials
  9. VAMP8 suppresses the metastasis via DDX5/β-catenin signal pathway in osteosarcoma.2023Cancer biology & therapy
  10. Anti-Her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance.2023Journal of nanobiotechnology
  11. Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy.2022Drug delivery
  12. A novel nomogram and risk classification system predicting the Ewing sarcoma: a population-based study.2022Scientific reports
  13. Cisplatin inhibits the proliferation of Saos-2 osteosarcoma cells via the miR-376c/TGFA pathway.2021Bosnian journal of basic medical sciences
早期论文(2016–2020 年)5
  1. Hsa_circ_0003732 promotes osteosarcoma cells proliferation via miR-545/CCNA2 axis.2020Bioscience reports
  2. Cold atmospheric plasma‑activated Ringer's solution inhibits the proliferation of osteosarcoma cells through the mitochondrial apoptosis pathway.2020Oncology reports
  3. Long noncoding RNA Breast cancer antiestrogen resistance 4 is associated with cancer progression and its significant prognostic value.2019Journal of cellular physiology
  4. A predictive model to estimate the pretest probability of metastasis in patients with osteosarcoma.2017Medicine
  5. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].2016Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

合肥有 3 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

合肥有 6 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

合肥有 2 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 2220232024: 2220242025: 112025

合肥有 5 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层联合用药肾脏与骨骼并发症
论文中的科室病理/检验科风湿免疫科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. WTAP promotes the proliferation of multiple myeloma by regulating the hippo pathway through m6A modification of MAP6D1.2026Leukemia & lymphoma
  2. Dynamic monitoring of M-protein quantification by immunotyping using capillary zone electrophoresis during the chemotherapy of patients with multiple myeloma.2025Scientific reports免费全文
  3. Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin.2024Laboratory medicine
  4. N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1.2024Molecular and cellular biochemistry
  5. Evolving roles of CD38 metabolism in solid tumour microenvironment.2023British journal of cancer免费全文
  6. Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature review.2023Immunity, inflammation and disease免费全文
  7. LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.2022Cell biology and toxicology
  8. Acupuncture-exacerbated pyoderma gangrenosum associated with IgG multiple myeloma.2022Wounds : a compendium of clinical research and practice
  9. Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis.2021Leukemia research
  10. Long non‑coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR‑135b‑5p to target KLF9.2021Molecular medicine reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  2. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  3. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy已完成NCT02609828研究中心III期2015-10 启动
  4. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)已终止NCT01947309研究中心2013-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

合肥有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

合肥有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室风湿免疫科
牵头的论文2
  1. Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.2024Frontiers of medicine
  2. A case report of systemic lupus erythematosus presented as thrombotic thrombocytopenic purpura and successfully treated with plasmapheresis and belimumab.2022Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

合肥有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

合肥有 2 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除生物制剂与补体抑制剂抗体与诊断
论文中的科室神经内科放疗科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

合肥有 4 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
    分期
    早期I期
    开始
    2025-12
    登记号
    NCT07240896

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心合肥

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传学(ATP7B)脑部与运动症状
论文中的科室影像/核医学科
牵头的论文1
  1. Changes in brain susceptibility in Wilson's disease patients: a quantitative susceptibility mapping study.2024Clinical radiology
中文论文(未计入)1
  1. [Research progresses in gene therapy for hepatolenticular degeneration].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)正在招募NCT07240896研究中心早期I期2025-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.6%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 1120232024: 1120242025: 222025

合肥有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

合肥有 1 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.5%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

合肥有 5 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

合肥有 1 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinical phenotypes and genetic features of families with Duchenne muscular dystrophy].2020Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.5%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 3320232024: 1120242025: 332025

合肥有 4 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科儿科肾内科
牵头的论文11
  1. POSTN promotes ferroptosis and contributes to the pathogenesis of IgA nephropathy via GPX4 downregulation.2025Acta histochemica
  2. Downregulation of CD36 alleviates IgA nephropathy by promoting autophagy and inhibiting extracellular matrix accumulation in mesangial cells.2025International immunopharmacology
  3. Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy.2025Renal failure
  4. Causal role of immune cells in IgA nephropathy: a mendelian randomization study.2024Renal failure
  5. A novel clinical-radiomic nomogram for the crescent status in IgA nephropathy.2023Frontiers in endocrinology
  6. Renal histopathological manifestations of IgA vasculitis nephritis in children and adults.2023International immunopharmacology
  7. Development of a novel combined nomogram model integrating deep learning radiomics to diagnose IgA nephropathy clinically.2023Renal failureRCT
  8. Chemokine (C-C motif) receptor 2 is associated with the pathological grade and inflammatory response in IgAN children.2022BMC nephrology
  9. Noninvasive evaluation of IgA nephropathy fibrosis using Doppler ultrasound.2022Renal failure
  10. A Pooled Study of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism in Relation to Risk, Pathology and Prognosis of Childhood Immunoglobulin A Vasculitis Nephritis.2021Biochemical genetics
  11. Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy.2021International urology and nephrology
早期论文(2016–2020 年)1
  1. IgG deposits in the mesangium and capillary loops predict poor renal outcome in patients with IgA nephropathy: a single-center retrospective study.2020Renal failure
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

合肥有 1 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

合肥有 3 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

合肥有 4 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年没有牵头先天性膈疝的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

合肥有 2 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Bochdalek hernia.2018Lancet (London, England)

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

合肥有 4 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

合肥有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

合肥有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

合肥有 1 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

安徽医科大学第一附属医院

First Affiliated Hospital of Anhui Medical University

合肥

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
First Affiliated Hospital of Anhui Medical University (AHMU); First affiliated Hospital of Anhui Medical University; P.R. China The First Affiliated Hospital of Anhui Medical University

提出更正下载数据